Nakajima K.Critical role of the interleukin-23/T-helper 17 cell axis in the pathogenesis of psoriasis. J Dermatol 39:219-224

Department of Dermatology, Kochi Medical School, Kochi University, Kochi, Japan.
The Journal of Dermatology (Impact Factor: 2.25). 03/2012; 39(3):219-24. DOI: 10.1111/j.1346-8138.2011.01458.x
Source: PubMed


Psoriasis is an inflammatory disease with dynamic interactions between the immune system and the skin. Recent studies have demonstrated that the interleukin (IL)-23/T-helper (Th)17 cell axis plays an important role in the pathogenesis of psoriasis. Here, the biology and function of Th17 cells as well as the crucial role of IL-23 in the context of the Th17 cell-dependent chronic inflammation in psoriatic skins are reviewed. Recent study about the role of the IL-23/Th17 axis in the pathogenesis of psoriasis-like lesions in K5.Stat3C transgenic mice is also discussed. This model mouse for psoriasis not only verifies the therapeutic efficacies of biologics that specifically target the IL-23/Th17 axis, but also clarifies the pathogenesis of psoriasis.

15 Reads
  • Source
    • "In psoriasis, IL-23 is produced at high levels by DCs and keratinocytes, and this cytokine stimulates Th17 cells to produce IL-17A and IL-22. Several groups reported that psoriatic lesions showed increased mRNA levels of the IL- 23/Th17 axis, including IL-23p19, IL-12/23p40, IL-22, IL-17A, and IL-17F, whereas mRNA levels of IL-12p35 and IL-4 were not elevated [24] [25] [26]. Furthermore, evidence for the role of IL-23 in the pathogenesis of psoriasis was substantiated by the initiation of the psoriasis-like disease acanthosis following repeated injections of IL-23 in mice [12]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: T-helper 17 (Th17) cells are characterized by producing interleukin-17 (IL-17, also called IL-17A), IL-17F, IL-21, and IL-22 and potentially TNF- α and IL-6 upon certain stimulation. IL-23, which promotes Th17 cell development, as well as IL-17 and IL-22 produced by the Th17 cells plays essential roles in various inflammatory diseases, such as experimental autoimmune encephalomyelitis, rheumatoid arthritis, colitis, and Concanavalin A-induced hepatitis. In this review, we summarize the characteristics of the functional role of Th17 cells, with particular focus on the Th17 cell-related cytokines such as IL-17, IL-22, and IL-23, in mouse models and human inflammatory diseases.
    Clinical and Developmental Immunology 07/2013; 2013(14):968549. DOI:10.1155/2013/968549 · 2.93 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective To assess the safety and efficacy of secukinumab, a fully human monoclonal anti-interleukin-17A antibody, in patients with rheumatoid arthritis (RA). Methods Patients (n=237) with inadequate response to methotrexate were randomly assigned to receive monthly subcutaneous injections of secukinumab 25 mg, 75 mg, 150 mg, 300 mg or placebo. The primary endpoint was the American College of Rheumatology 20% response (ACR20) at week 16. Results Demographics and baseline characteristics were comparable across all treatment groups. The primary efficacy endpoint was not achieved: the proportion of ACR20 responders at week 16 with secukinumab 25–300 mg was 36.0–53.7% versus placebo (34%). Disease activity score in 28 joints (DAS28)–C-reactive protein (CRP) was a secondary endpoint and clinically relevant decreases with secukinumab 75–300 mg were reported versus placebo. Serum high sensitivity CRP levels at week 16 were significantly reduced with secukinumab 75 mg, 150 mg and 300 mg doses versus placebo. The safety profile of secukinumab was consistent with that seen with other biological agents. Most adverse events (AE) were mild to moderate in severity. Infections were slightly more frequent with secukinumab than placebo. Six serious AE were reported: secukinumab 75 mg (one), secukinumab 300 mg (four) and placebo (one). Conclusions ACR20 response rates differed between secukinumab 75 mg, 150 mg and 300 mg doses and placebo; however, the primary efficacy endpoint was not achieved. Greater decreases in DAS28 were observed with secukinumab 75 mg, 150 mg and 300 mg than placebo. There were no unexpected safety signals and no specific organ-related toxicities. Further trials with secukinumab in the treatment of RA are warranted.
    Annals of the rheumatic diseases 06/2012; 41(3). DOI:10.1136/annrheumdis-2012-201601 · 10.38 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Sjögren's syndrome (SjS) is a systemic autoimmune disease that primarily targets salivary and lacrimal glands. SjS affects 2-4 million people in the US alone and greatly affects the life quality of the afflicted individuals. Autoreactive effector T cells are central executors and orchestrators in the pathogenic processes of SjS by mediating target organ inflammation and destruction and by facilitating B cell responses and autoantibody production. A variety of cytokines that are produced by effector T cells or capable of directly affecting effector T cells are elevated in the target organs and circulations of SjS patients. The recent advancement in the understanding about the functions of these cytokines, achieved by using both human samples and mouse disease models, has generated great insights into the cytokine control of autoimmune responses in the SjS disease setting. In this review, we summarized the recent findings on the expression and functions of cytokines in this disease, with specific focus on those derived from T cells and/or directly affecting T cell responses.
    02/2013; S!(9). DOI:10.4172/2155-9899.S1-009
Show more

Similar Publications